Literature DB >> 11270936

Comparative review of topical ophthalmic antibacterial preparations.

P Y Robert1, J P Adenis.   

Abstract

The choice of an antibacterial is based on considerations of pharmacodynamic, pharmacokinetic and bacteriological characteristics, risk of selecting resistant mutants, and cost. In this article we review 16 commercially available ophthalmic antibacterial preparations. Fusidic acid and bacitracin are selective for gram-positive bacteria whereas polymyxin B targets gram-negative species. Aminoglycosides and quinolones are broad spectrum antibacterials. The widespread use of an antibacterial increases risks of selecting resistance to it. Acquired resistance is well documented for fusidic acid and rifamycin, and newly described for quinolones. The bioavailability of an antibacterial agent depends on the target bacterial species, the site of infection and the integrity of the haemato-aqueous barrier. Some agents (fusidic acid, quinolones) penetrate the cornea, passing into the anterior chamber of normal eyes at therapeutic concentrations, whereas others (polymixin B, bacitracin) have no penetrating powers and remain at the surface of the eye. Toxicity is mostly manifested by allergic reactions to excipients or active ingredients in topical antibacterial preparations. A few cases of haematological toxicity have brought suspicion on topical chloramphenicol, but the link has yet to be proven. Erythromycin and polymyxin B are probably okay to use as topical applications in pregnant women and nursing mothers. Costs of treatment must be evaluated as a whole (regimen, drug associations). Prices for a bottle of eyedrops may vary 3-fold. The cheapest drugs include chloramphenicol, polymyxin B and gentamicin, the most expensive being fusidic acid and the quinolones.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11270936     DOI: 10.2165/00003495-200161020-00003

Source DB:  PubMed          Journal:  Drugs        ISSN: 0012-6667            Impact factor:   9.546


  55 in total

1.  Ocular penetration of topically applied gentamicin.

Authors:  B Ellerhost; B Golden; N Jarudi
Journal:  Arch Ophthalmol       Date:  1975-05

2.  Is it time to stop using chloramphenicol on the eye? Fears are based on only six cases.

Authors:  R J Mulla; E Barnes; T R Rogers
Journal:  BMJ       Date:  1995-08-12

Review 3.  Ocular chloramphenicol and aplastic anaemia. Is there a link?

Authors:  S A Rayner; R J Buckley
Journal:  Drug Saf       Date:  1996-05       Impact factor: 5.606

4.  Penetration of gentamicin into the aphakic eye.

Authors:  G A Peyman; D R May; P I Homer; R T Kasbeer
Journal:  Ann Ophthalmol       Date:  1977-07

5.  Fatal aplastic anemia following topical administration of ophthalmic chloramphenicol.

Authors:  F T Fraunfelder; G C Bagby; D J Kelly
Journal:  Am J Ophthalmol       Date:  1982-03       Impact factor: 5.258

6.  Contact allergy to components in topical ophthalmologic preparations.

Authors:  A Hätinen; M Teräsvirta; J E Fräki
Journal:  Acta Ophthalmol (Copenh)       Date:  1985-08

7.  [Corneal penetration of various aminoglycosides and quinolones].

Authors:  K Luthardt; R Beck; E M Hehl; G Kundt; B Drewelow; R Guthoff
Journal:  Klin Monbl Augenheilkd       Date:  1998-09       Impact factor: 0.700

8.  Comparison of aqueous humour and vitreous humour levels of two 0.3% ciprofloxacin eyedrops.

Authors:  O Cekiç; C Batman; U Yasar; N E Basci; A Bozkurt; S O Kayaalp
Journal:  Can J Ophthalmol       Date:  1998-12       Impact factor: 1.882

9.  Use of collagen corneal shields in the treatment of bacterial keratitis.

Authors:  M R Sawusch; T P O'Brien; J D Dick; J D Gottsch
Journal:  Am J Ophthalmol       Date:  1988-09-15       Impact factor: 5.258

10.  Topical 0.3% ciprofloxacin, norfloxacin, and ofloxacin in treatment of bacterial keratitis: a new method for comparative evaluation of ocular drug penetration.

Authors:  J P Diamond; L White; J P Leeming; H Bing Hoh; D L Easty
Journal:  Br J Ophthalmol       Date:  1995-06       Impact factor: 4.638

View more
  9 in total

1.  A novel cell-associated protection assay demonstrates the ability of certain antibiotics to protect ocular surface cell lines from subsequent clinical Staphylococcus aureus challenge.

Authors:  J B Wingard; E G Romanowski; R P Kowalski; F S Mah; Y Ling; R A Bilonick; R M Q Shanks
Journal:  Antimicrob Agents Chemother       Date:  2011-05-31       Impact factor: 5.191

Review 2.  Topical treatments for blepharokeratoconjunctivitis in children.

Authors:  Michael O'Gallagher; Catey Bunce; Melanie Hingorani; Frank Larkin; Stephen Tuft; Annegret Dahlmann-Noor
Journal:  Cochrane Database Syst Rev       Date:  2017-02-07

3.  Antibacterial and Antibiofilm Potency of XF Drugs, Impact of Photodynamic Activation and Synergy With Antibiotics.

Authors:  Emma Louise Board-Davies; William Rhys-Williams; Daniel Hynes; David Williams; Damian Joseph John Farnell; William Love
Journal:  Front Cell Infect Microbiol       Date:  2022-06-30       Impact factor: 6.073

4.  Efficacy of treatments for neurotrophic keratopathy: a systematic review and meta-analysis.

Authors:  Sébastien Roumeau; Frédéric Dutheil; Vincent Sapin; Julien S Baker; Stephanie L Watson; Bruno Pereira; Frédéric Chiambaretta; Valentin Navel
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2022-03-07       Impact factor: 3.535

5.  Etiology and epidemiological analysis of glaucoma-filtering bleb infections in a tertiary eye care hospital in South India.

Authors:  R Ramakrishnan; M Jayahar Bharathi; Devendra Maheshwari; P M T Mohideen; Mona Khurana; C Shivakumar
Journal:  Indian J Ophthalmol       Date:  2011 Nov-Dec       Impact factor: 1.848

6.  Characteristics of corneal phospholipidosis induced by topical ocular application of chloroquine and amiodarone in rabbits.

Authors:  Yoshinori Yamagiwa; Yu Haranosono; Shingo Nemoto; Ikuyo Atsumi; Masaaki Kurata; Gakushi Kito; Hirofumi Hatakeyama; Haruko Koizumi; Hideyuki Sakaki
Journal:  J Toxicol Pathol       Date:  2016-11-27       Impact factor: 1.628

Review 7.  Review of Loteprednol Etabonate 0.5%/Tobramycin 0.3% in the Treatment of Blepharokeratoconjunctivitis.

Authors:  Francis S Mah; Paul M Karpecki
Journal:  Ophthalmol Ther       Date:  2021-10-27

8.  Eudragit® L100/Polyvinyl Alcohol Nanoparticles Impregnated Mucoadhesive Films as Ocular Inserts for Controlled Delivery of Erythromycin: Development, Characterization and In Vivo Evaluation.

Authors:  Shahla Mirzaeei; Shiva Taghe; Raid G Alany; Ali Nokhodchi
Journal:  Biomedicines       Date:  2022-08-08

9.  Impact of Topically Administered Steroids, Antibiotics, and Sodium Hyaluronate on Bleb-Related Infection Onset: The Japan Glaucoma Society Survey of Bleb-Related Infection Report 4.

Authors:  Hideto Sagara; Tetsuya Yamamoto; Kimihiro Imaizumi; Tetsuju Sekiryu
Journal:  J Ophthalmol       Date:  2017-09-12       Impact factor: 1.909

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.